Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations
Latest Information Update: 21 Dec 2024
Price :
$35 *
At a glance
- Drugs Zongertinib (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms Beamion Lung 1
- Sponsors Boehringer Ingelheim
- 01 Oct 2024 Planned primary completion date changed from 31 Dec 2025 to 31 Mar 2026.
- 19 Sep 2024 Planned End Date changed from 31 Dec 2027 to 28 Jan 2028.
- 27 Aug 2024 According to a Boehringer Ingelheim media release, ew data from a primary analysis of the first Cohort of Phase Ib in pre-treated patients with HER2m+ NSCLC to be presented in a Presidential Symposium on Monday, September 9, from 8:30AM - 10:00AM PDT (Location: Plenary Hall) and featured in the official WCLC Press Program.